Unicycive Therapeutics Inc
UNCY
View Detailed Chart
4.620USD
0.000
Close 10/03, 16:00（ET）Quotes delayed by 15 min
65.20MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+14.93%
1 Month
+5.96%
6 Months
+795.52%
Year to Date
+481.72%
1 Year
+1136.29%
View Detailed Chart
TradingKey Stock Score of Unicycive Therapeutics Inc
Currency: USD Updated: 2025-10-03Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Unicycive Therapeutics Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
63.125
Target Price
+1266.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Unicycive Therapeutics Inc Highlights
StrengthsRisks
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 109.46.
Undervalued
The company’s latest PE is -1.66, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.48M shares, decreasing 21.06% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 605.95K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.79.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Unicycive Therapeutics Inc Info
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
Ticker SymbolUNCY
CompanyUnicycive Therapeutics Inc
CEODr. Shalabh Gupta, M.D.
Websitehttps://unicycive.com/
Related Instruments
+1.06%
+0.89%
+1.08%
-0.38%
+2.85%
+0.94%
+2.68%
+2.64%
+0.48%
-0.69%
+1.53%
+1.10%
-3.05%
+0.94%
+2.31%
+1.20%
-1.47%
+1.39%
+2.21%
+1.16%Popular Symbols
